SR-BI targeting E2 mAb (Rappaport)

N/A

Report date: 2025/03/20 14:44:16

Base Information

Drug NameSR-BI targeting E2 mAb (Rappaport)
Drug Alias Namescavenger receptor class B member 1 targeting E2 mAb (Rappaport)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionScavenger receptor class B member 1 modulators
TargetsScavenger receptor class B member 1
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRappaport Family Institute for Research in the Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesBioRap Technologies LtdRappaport Family Institute for Research in the Medical Sciences
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A